-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirodenafil Dihydrochloride in Post-Traumatic Stress Disorder (PTSD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirodenafil Dihydrochloride in Post-Traumatic Stress Disorder (PTSD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirodenafil Dihydrochloride in Post-Traumatic Stress Disorder (PTSD) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Romidepsin in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Romidepsin in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Romidepsin in Breast Cancer Drug Details: Romidepsin (Istodax) is an antineoplastic agent....
-
Product Insights
Vascular Dementias – Drugs In Development, 2023
Global Markets Direct’s, ‘Vascular Dementias - Drugs In Development, 2023’, provides an overview of the Vascular Dementias pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vascular Dementias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Lewy Body Dementia – Drugs In Development, 2023
Global Markets Direct’s, ‘Lewy Body Dementia - Drugs In Development, 2023’, provides an overview of the Lewy Body Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lewy Body Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Rett Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Rett Syndrome - Drugs In Development, 2023’, provides an overview of the Rett Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rett Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Mild Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Mild Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Mild Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Post-Traumatic Stress Disorder (PTSD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Traumatic Stress Disorder (PTSD) - Drugs In Development, 2023’, provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NTX-1088 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NTX-1088 in Solid Tumor Drug Details: NTX-1088 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mirodenafil Dihydrochloride in Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mirodenafil Dihydrochloride in Alzheimer's Disease Drug Details: AR-1001 is under development for the treatment of...